Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × elotuzumab × Lymphoid × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 11 Lymphoid 1

Conditions

Multiple Myeloma 1 Lymphoma 1

Interventions

Rituximab 215 Cyclophosphamide 178 Vincristine 151 Doxorubicin 142 Prednisone 118 Etoposide 73 Methotrexate 71 Cytarabine 71 Dexamethasone 64 Radiotherapy 56 Bendamustine Hydrochloride 54 Mercaptopurine 42 Lenalidomide 40 pegaspargase 38 Filgrastim 36 Prednisolone 35 Daunorubicin 33 Bleomycin 33 ibrutinib 32 fludarabine 32 obinutuzumab 30 Asparaginase 29 Gemcitabine 26 Leucovorin 25 Granulocyte Colony-Stimulating Factor 25 venetoclax 24 Chlorambucil 24 Calcium Dobesilate 24 Vinblastine 23 Thioguanine 22

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01239797 2022-06-01

ELOQUENT - 2

Bristol-Myers Squibb

Phase 3 Completed

646 enrolled 16 charts

LymphoidPlasma cell

Lymphoma, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡